While pembrolizumab threshold is PD-L1 positivity of > 10% and based on combined score of both tumor and inflammatory cells, Atezolizumab threshold is PDL-1 positivity of > 1% in immune cells [10]. This evidence concerns the gene CD274 and neoplasm.